Engineering therapeutic monoclonal antibodies.

Area of Science:

• Immunology
• Biotechnology
• Pharmacology

Background:

• Monoclonal antibodies (mAbs) have revolutionized treatments for cancer, autoimmune diseases, and transplant rejection through chimerization and humanization.
• Further improvements in mAb efficacy involve combination therapies and molecular redesign for enhanced in vivo activity.

Discussion:

• Redesign strategies leverage new insights into immunoglobulin G (IgG) interactions with Fc receptors and complement.
• Mutations in the Fc portion of mAbs optimize effector functions, pharmacokinetics, and signaling.
• Increased mAb valency reduces dissociation rates and enhances apoptosis induction.

Key Insights:

• Engineered mAbs exhibit improved pharmacokinetic profiles and effector functions.
• Enhanced valency contributes to increased therapeutic efficacy, including apoptosis induction.
• Understanding Fc receptor and complement interactions is crucial for mAb design.

Outlook:

• Continued evaluation of redesigned mAbs in vitro and in vivo is essential.
• Further optimization of mAb design holds promise for next-generation therapeutics.
• Exploring novel combination strategies will expand therapeutic applications.